VOGLI RPD.3/1

About

VOGLI RPD.3/1 is a combination medication designed for the advanced management of type 2 diabetes mellitus, typically combining an alpha-glucosidase inhibitor (like Voglibose), a thiazolidinedione (like Pioglitazone), and a biguanide (like Metformin). This triple-action therapy targets multiple pathophysiological defects of type 2 diabetes. Voglibose delays carbohydrate absorption, Pioglitazone improves insulin sensitivity in peripheral tissues and the liver, and Metformin reduces hepatic glucose production while enhancing insulin action. This comprehensive approach helps to achieve sustained glycemic control by reducing both postprandial and fasting blood glucose levels.

This formulation is indicated for adult patients who have not achieved adequate glycemic control with monotherapy or dual therapy, or when a multi-faceted approach is deemed necessary by a healthcare professional. The combination aims to lower HbA1c levels, improve overall metabolic parameters, and reduce the risk of long-term microvascular and macrovascular complications associated with diabetes. Regular monitoring of blood glucose, HbA1c, and liver function is crucial to ensure safety and efficacy.

Uses

• Management of type 2 diabetes mellitus.
• Improved glycemic control in adults.
• Reduction of postprandial and fasting blood glucose.
• When monotherapy or dual therapy is insufficient.

Directions For Use

Take this medication orally with meals, as directed by your physician. Do not crush or chew the tablets.

Benefits

• Comprehensive blood glucose control.
• Significant reduction in HbA1c levels.
• Improved insulin sensitivity.
• Effective management of post-meal sugar spikes.
• Reduced risk of long-term diabetic complications.
• Synergistic action of multiple antidiabetic agents.

Side Effects

• Nausea
• Diarrhea
• Abdominal pain
• Flatulence
• Headache
• Dizziness
• Weight gain
• Fluid retention/Edema
• Metallic taste
• Lactic acidosis (rare, serious)
• Bone fractures (with Pioglitazone)
• Upper respiratory tract infection

Safety Measures

• Alcohol - Avoid excessive alcohol consumption as it can increase the risk of hypoglycemia and lactic acidosis, especially with Metformin.
• Pregnancy - Generally not recommended during pregnancy. Consult your doctor; insulin is often preferred for glycemic control in pregnant women.
• Breastfeeding - Not recommended during breastfeeding as components may pass into breast milk and potentially affect the infant.
• Liver - Contraindicated in active liver disease due to Pioglitazone. Use with caution in patients with liver impairment; Metformin metabolism can be affected.
• Kidney - Contraindicated in severe renal impairment (e.g., eGFR <30 mL/min/1.73m²) due to increased risk of lactic acidosis with Metformin. Use with caution due to fluid retention risk with Pioglitazone.
• Lung - Use with caution in patients with severe lung conditions, as it may exacerbate conditions that predispose to lactic acidosis.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.